APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rotavirus Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rotavirus Infections Drug Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchRotavirus Infections Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Rotavirus Infections Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Rotavirus Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rotavirus Infections Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Rotavirus Infections Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Rotavirus Infections Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rotavirus Infections Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rotavirus Infections Drug market include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rotavirus Infections Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rotavirus Infections Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rotavirus Infections Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rotavirus Infections Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Rotavirus Infections Drug Segment by Company

Wuhan Institute of Biological Products Co Ltd

Beijing Minhai Biotechnology Co Ltd

UMN Pharma Inc

Serum Institute of India Ltd

Nanotherapeutics Inc

Medicago Inc

Curevac AG

Biological E Ltd

Bharat Biotech International Ltd

Rotavirus Infections Drug Segment by Type

UMN-2001

RV-625

RV-3BB

Rotavac-5C

Others

Rotavirus Infections Drug Segment by Application

Clinic

Hospital

Others

Rotavirus Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rotavirus Infections Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Rotavirus Infections Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rotavirus Infections Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Rotavirus Infections Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rotavirus Infections Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rotavirus Infections Drug industry.

Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Rotavirus Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Rotavirus Infections Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rotavirus Infections Drug Industry Trends Table 2. Rotavirus Infections Drug Industry Drivers Table 3. Rotavirus Infections Drug Industry Opportunities and Challenges Table 4. Rotavirus Infections Drug Industry Restraints Table 5. Global Rotavirus Infections Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rotavirus Infections Drug Revenue Share by Company (2021-2026) Table 7. Global Rotavirus Infections Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Rotavirus Infections Drug Sales Volume Share by Company (2021-2026) Table 9. Global Rotavirus Infections Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Rotavirus Infections Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Rotavirus Infections Drug Key Company Manufacturing Base & Headquarters Table 12. Global Rotavirus Infections Drug Company, Product Type & Application Table 13. Global Rotavirus Infections Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Rotavirus Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of UMN-2001 Table 18. Significant Companies of RV-625 Table 19. Significant Companies of RV-3BB Table 20. Significant Companies of Rotavac-5C Table 21. Significant Companies of Others Table 22. Global Rotavirus Infections Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Rotavirus Infections Drug Sales Volume by Type (2021-2026) & (k units) Table 24. Global Rotavirus Infections Drug Sales Volume by Type (2027-2032) & (k units) Table 25. Global Rotavirus Infections Drug Sales Volume Share by Type (2021-2026) Table 26. Global Rotavirus Infections Drug Sales Volume Share by Type (2027-2032) Table 27. Global Rotavirus Infections Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Rotavirus Infections Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Rotavirus Infections Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Rotavirus Infections Drug Sales Value Share by Type (2021-2026) Table 31. Global Rotavirus Infections Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Others Table 35. Global Rotavirus Infections Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Rotavirus Infections Drug Sales Volume by Application (2021-2026) & (k units) Table 37. Global Rotavirus Infections Drug Sales Volume by Application (2027-2032) & (k units) Table 38. Global Rotavirus Infections Drug Sales Volume Share by Application (2021-2026) Table 39. Global Rotavirus Infections Drug Sales Volume Share by Application (2027-2032) Table 40. Global Rotavirus Infections Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Rotavirus Infections Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Rotavirus Infections Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Rotavirus Infections Drug Sales Value Share by Application (2021-2026) Table 44. Global Rotavirus Infections Drug Sales Value Share by Application (2027-2032) Table 45. Global Rotavirus Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Rotavirus Infections Drug Sales by Region (2021-2026) & (k units) Table 47. Global Rotavirus Infections Drug Sales Market Share by Region (2021-2026) Table 48. Global Rotavirus Infections Drug Sales by Region (2027-2032) & (k units) Table 49. Global Rotavirus Infections Drug Sales Market Share by Region (2027-2032) Table 50. Global Rotavirus Infections Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Rotavirus Infections Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Rotavirus Infections Drug Sales Value Share by Region (2021-2026) Table 53. Global Rotavirus Infections Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Rotavirus Infections Drug Sales Value Share by Region (2027-2032) Table 55. Global Rotavirus Infections Drug Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Rotavirus Infections Drug Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Rotavirus Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Rotavirus Infections Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 60. Global Rotavirus Infections Drug Sales Market Share by Country (2021-2026) Table 61. Global Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 62. Global Rotavirus Infections Drug Sales Market Share by Country (2027-2032) Table 63. Global Rotavirus Infections Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Rotavirus Infections Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Rotavirus Infections Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Rotavirus Infections Drug Sales Value Market Share by Country (2027-2032) Table 67. Wuhan Institute of Biological Products Co Ltd Company Information Table 68. Wuhan Institute of Biological Products Co Ltd Business Overview Table 69. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio Table 71. Wuhan Institute of Biological Products Co Ltd Recent Development Table 72. Beijing Minhai Biotechnology Co Ltd Company Information Table 73. Beijing Minhai Biotechnology Co Ltd Business Overview Table 74. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio Table 76. Beijing Minhai Biotechnology Co Ltd Recent Development Table 77. UMN Pharma Inc Company Information Table 78. UMN Pharma Inc Business Overview Table 79. UMN Pharma Inc Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. UMN Pharma Inc Rotavirus Infections Drug Product Portfolio Table 81. UMN Pharma Inc Recent Development Table 82. Serum Institute of India Ltd Company Information Table 83. Serum Institute of India Ltd Business Overview Table 84. Serum Institute of India Ltd Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio Table 86. Serum Institute of India Ltd Recent Development Table 87. Nanotherapeutics Inc Company Information Table 88. Nanotherapeutics Inc Business Overview Table 89. Nanotherapeutics Inc Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio Table 91. Nanotherapeutics Inc Recent Development Table 92. Medicago Inc Company Information Table 93. Medicago Inc Business Overview Table 94. Medicago Inc Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Medicago Inc Rotavirus Infections Drug Product Portfolio Table 96. Medicago Inc Recent Development Table 97. Curevac AG Company Information Table 98. Curevac AG Business Overview Table 99. Curevac AG Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Curevac AG Rotavirus Infections Drug Product Portfolio Table 101. Curevac AG Recent Development Table 102. Biological E Ltd Company Information Table 103. Biological E Ltd Business Overview Table 104. Biological E Ltd Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Biological E Ltd Rotavirus Infections Drug Product Portfolio Table 106. Biological E Ltd Recent Development Table 107. Bharat Biotech International Ltd Company Information Table 108. Bharat Biotech International Ltd Business Overview Table 109. Bharat Biotech International Ltd Rotavirus Infections Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio Table 111. Bharat Biotech International Ltd Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Rotavirus Infections Drug Distributors List Table 115. Rotavirus Infections Drug Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Rotavirus Infections Drug Product Image Figure 2. Global Rotavirus Infections Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rotavirus Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Rotavirus Infections Drug Sales (2021-2032) & (k units) Figure 5. Global Rotavirus Infections Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Rotavirus Infections Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. UMN-2001 Image Figure 10. RV-625 Image Figure 11. RV-3BB Image Figure 12. Rotavac-5C Image Figure 13. Others Image Figure 14. Global Rotavirus Infections Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Rotavirus Infections Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Rotavirus Infections Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Rotavirus Infections Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Rotavirus Infections Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Rotavirus Infections Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Rotavirus Infections Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Rotavirus Infections Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Rotavirus Infections Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Rotavirus Infections Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Rotavirus Infections Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Rotavirus Infections Drug Sales Value Share by Application (2021-2032) Figure 29. Global Rotavirus Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Rotavirus Infections Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Rotavirus Infections Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Rotavirus Infections Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Rotavirus Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Rotavirus Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Rotavirus Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Rotavirus Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Rotavirus Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Rotavirus Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Rotavirus Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Rotavirus Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Rotavirus Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Rotavirus Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Rotavirus Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Rotavirus Infections Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Rotavirus Infections Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • UMN-2001
  • RV-625
  • RV-3BB
  • Rotavac-5C
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Wuhan Institute of Biological Products Co Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • UMN Pharma Inc
  • Serum Institute of India Ltd
  • Nanotherapeutics Inc
  • Medicago Inc
  • Curevac AG
  • Biological E Ltd
  • Bharat Biotech International Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Rotavirus Infections Drug Sales Value (2021-2032)
  4. 1.2.2 Global Rotavirus Infections Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Rotavirus Infections Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Rotavirus Infections Drug Market Dynamics
  1. 2.1 Rotavirus Infections Drug Industry Trends
  2. 2.2 Rotavirus Infections Drug Industry Drivers
  3. 2.3 Rotavirus Infections Drug Industry Opportunities and Challenges
  4. 2.4 Rotavirus Infections Drug Industry Restraints
3 Rotavirus Infections Drug Market by Company
  1. 3.1 Global Rotavirus Infections Drug Company Revenue Ranking in 2025
  2. 3.2 Global Rotavirus Infections Drug Revenue by Company (2021-2026)
  3. 3.3 Global Rotavirus Infections Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Rotavirus Infections Drug Average Price by Company (2021-2026)
  5. 3.5 Global Rotavirus Infections Drug Company Ranking (2024-2026)
  6. 3.6 Global Rotavirus Infections Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Rotavirus Infections Drug Company Product Type and Application
  8. 3.8 Global Rotavirus Infections Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Rotavirus Infections Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Rotavirus Infections Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Rotavirus Infections Drug Market by Type
  1. 4.1 Rotavirus Infections Drug Type Introduction
  2. 4.1.1 UMN-2001
  3. 4.1.2 RV-625
  4. 4.1.3 RV-3BB
  5. 4.1.4 Rotavac-5C
  6. 4.1.5 Others
  7. 4.2 Global Rotavirus Infections Drug Sales Volume by Type
  8. 4.2.1 Global Rotavirus Infections Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Rotavirus Infections Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Rotavirus Infections Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Rotavirus Infections Drug Sales Value by Type
  12. 4.3.1 Global Rotavirus Infections Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Rotavirus Infections Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Rotavirus Infections Drug Sales Value Share by Type (2021-2032)
5 Rotavirus Infections Drug Market by Application
  1. 5.1 Rotavirus Infections Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Rotavirus Infections Drug Sales Volume by Application
  6. 5.2.1 Global Rotavirus Infections Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Rotavirus Infections Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Rotavirus Infections Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Rotavirus Infections Drug Sales Value by Application
  10. 5.3.1 Global Rotavirus Infections Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Rotavirus Infections Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Rotavirus Infections Drug Sales Value Share by Application (2021-2032)
6 Rotavirus Infections Drug Regional Sales and Value Analysis
  1. 6.1 Global Rotavirus Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rotavirus Infections Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Rotavirus Infections Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Rotavirus Infections Drug Sales by Region (2027-2032)
  5. 6.3 Global Rotavirus Infections Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Rotavirus Infections Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Rotavirus Infections Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Rotavirus Infections Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Rotavirus Infections Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Rotavirus Infections Drug Sales Value (2021-2032)
  12. 6.6.2 North America Rotavirus Infections Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Rotavirus Infections Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Rotavirus Infections Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Rotavirus Infections Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Rotavirus Infections Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Rotavirus Infections Drug Sales Value (2021-2032)
  21. 6.9.2 South America Rotavirus Infections Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Rotavirus Infections Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Rotavirus Infections Drug Sales Value Share by Country, 2025 VS 2032
7 Rotavirus Infections Drug Country-level Sales and Value Analysis
  1. 7.1 Global Rotavirus Infections Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rotavirus Infections Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Rotavirus Infections Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Rotavirus Infections Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Rotavirus Infections Drug Sales by Country (2027-2032)
  6. 7.4 Global Rotavirus Infections Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Rotavirus Infections Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Rotavirus Infections Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Rotavirus Infections Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Rotavirus Infections Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Rotavirus Infections Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Wuhan Institute of Biological Products Co Ltd
  2. 8.1.1 Wuhan Institute of Biological Products Co Ltd Company Information
  3. 8.1.2 Wuhan Institute of Biological Products Co Ltd Business Overview
  4. 8.1.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
  6. 8.1.5 Wuhan Institute of Biological Products Co Ltd Recent Developments
  7. 8.2 Beijing Minhai Biotechnology Co Ltd
  8. 8.2.1 Beijing Minhai Biotechnology Co Ltd Company Information
  9. 8.2.2 Beijing Minhai Biotechnology Co Ltd Business Overview
  10. 8.2.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
  12. 8.2.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
  13. 8.3 UMN Pharma Inc
  14. 8.3.1 UMN Pharma Inc Company Information
  15. 8.3.2 UMN Pharma Inc Business Overview
  16. 8.3.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
  18. 8.3.5 UMN Pharma Inc Recent Developments
  19. 8.4 Serum Institute of India Ltd
  20. 8.4.1 Serum Institute of India Ltd Company Information
  21. 8.4.2 Serum Institute of India Ltd Business Overview
  22. 8.4.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
  24. 8.4.5 Serum Institute of India Ltd Recent Developments
  25. 8.5 Nanotherapeutics Inc
  26. 8.5.1 Nanotherapeutics Inc Company Information
  27. 8.5.2 Nanotherapeutics Inc Business Overview
  28. 8.5.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
  30. 8.5.5 Nanotherapeutics Inc Recent Developments
  31. 8.6 Medicago Inc
  32. 8.6.1 Medicago Inc Company Information
  33. 8.6.2 Medicago Inc Business Overview
  34. 8.6.3 Medicago Inc Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Medicago Inc Rotavirus Infections Drug Product Portfolio
  36. 8.6.5 Medicago Inc Recent Developments
  37. 8.7 Curevac AG
  38. 8.7.1 Curevac AG Company Information
  39. 8.7.2 Curevac AG Business Overview
  40. 8.7.3 Curevac AG Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Curevac AG Rotavirus Infections Drug Product Portfolio
  42. 8.7.5 Curevac AG Recent Developments
  43. 8.8 Biological E Ltd
  44. 8.8.1 Biological E Ltd Company Information
  45. 8.8.2 Biological E Ltd Business Overview
  46. 8.8.3 Biological E Ltd Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biological E Ltd Rotavirus Infections Drug Product Portfolio
  48. 8.8.5 Biological E Ltd Recent Developments
  49. 8.9 Bharat Biotech International Ltd
  50. 8.9.1 Bharat Biotech International Ltd Company Information
  51. 8.9.2 Bharat Biotech International Ltd Business Overview
  52. 8.9.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
  54. 8.9.5 Bharat Biotech International Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rotavirus Infections Drug Value Chain Analysis
  2. 9.1.1 Rotavirus Infections Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rotavirus Infections Drug Sales Mode & Process
  6. 9.2 Rotavirus Infections Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rotavirus Infections Drug Distributors
  9. 9.2.3 Rotavirus Infections Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst